Given that FGFR4 inhibitors are currently in early-stage clinical trials for treatment, this protein, a target of autoantibodies, is of interest as a druggable target in BC, CRC, and hepatocellular cancers (195). This evidence concerns the gene FGFR4 and colorectal carcinoma.